ProSomnus, MonitAir collaborate to facilitate clinical visibility into OSA

SAN FRANCISCO – ProSomnus Sleep Technologies and MonitAir, a digital health and telemonitoring platform for sleep medicine, have collaborated to support connected, longitudinal and personalized care for patients with obstructive sleep apnea (OSA). Through this collaboration, healthcare providers who prescribe a ProSomnus RPMO₂ OSA Device will be able to view, organize and remotely monitor patient data within the MonitAir platform. The companies say the integration is intended to facilitate clinical visibility into patient status over multiple nights and to support coordination of care across clinical workflows. “Despite well-documented health, quality of life, and economic consequences, OSA remains undertreated due to fundamental limitations in how the condition is measured and managed – including night-to-night variability, reliance on frequency-based metrics that may not fully reflect health risk, and limited connectivity between patients and providers,” said Len Liptak, CEO of ProSomnus Sleep Technologies. “Our collaboration with MonitAir is designed to address these limitations in OSA care by enabling longitudinal remote monitoring of physiologic data generated by the ProSomnus RPMO₂ OSA Device—supporting a more connected, data-driven, and personalized approach to care and helping expand access to treatment.” The ProSomnus RPMO₂ OSA Device, which has Class II clearance from the U.S. Food and Drug Administration (FDA), incorporates a pulse oximeter embedded into the buccal mucosal region of a maxillary dental overlay, intended to measure, display, store, and transmit oxygen saturation and pulse rate. The device is designed for continuous data collection during use in clinical and home settings.

• Related: ProSomnus receives $38M investment to grow in alternative sleep market.